Clinical trial NCT05111665: Decentering and Relapse/Recurrence in MBCT for Depression in Adults
Official title: The Association Between Decentering and Reductions in Relapse/Recurrence in Mindfulness-Based Cognitive Therapy for Depression in Adults: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Depressive Disorder, Major
Depression in Remission
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2021-11-08
Enrollment: 227
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions. The current study sought to examine the role of decentering, and other related variables, in the efficacy of Mindfulness-based cognitive therapy (MBCT) as compared to two active comparison conditions.

Method: Formerly depressed individuals (N = 227), randomly assigned to MBCT (n = 74), relaxation group therapy (RGT; n = 77) or treatment-as-usual (TAU; n = 76), completed self-report measures of decentering and symptoms of depression at pre-, mid-, and post-treatment, and relapse was assessed at 3, 6, 9, and 12 months, post-treatment.


Eligibility criteria: Inclusion Criteria:

* a Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM IV-TR; American Psychiatric Association (APA), diagnosis of major depressive disorder (MDD) without psychotic features, in Full Remission;
* three or more prior major depressive episodes;
* age between 18 and 65 years;
* cognitive reactivity (CR) or mood-activated dysfunctional beliefs score greater than or equal to eight (see assessment procedure below);
* a score of less than 10 on the Hamilton Rating Scale for Depression (HRSD);
* minimum of a 10 week period free of psychotropic medication other than stable dosage of antidepressant medication for a minimum of four weeks;
* fluency in English; An increased cognitive reactivity score of eight points or more and,
* ability to give informed consent and complete questionnaires unassisted.

Exclusion Criteria:

* a diagnosis of bipolar disorder (past or present), schizophreniform disorders, substance abuse or dependence (current or within the past six months), borderline or antisocial personality disorder, or neurocognitive disorders;
* current psychotherapy or counselling more frequently than twice per month;
* current practice of meditation more than once per week or yoga more than twice per week;
* electroconvulsive therapy within the past six months; or
* self-reported ingestion of alcohol or other psychoactive substances within the past 48 hrs.

Primary outcomes:
measure: Major depressive disorder (MDD) relapse/recurrence - incidence of
timeFrame: 12- month post-treatment follow-up
measure: Change in major depressive disorder (MDD) relapse/recurrence - time to relapse/recurrence
timeFrame: 3-, 6-, 9-, and 12- month post-treatment follow-up
Secondary outcomes:
measure: Change in Beck Depression Inventory - Second Edition total scores
timeFrame: Pre-, mid- (i.e., at week 4 of MBCT), and post-treatment (i.e., after 8 weeks of MBCT)
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Mark Lau
state: British Columbia
Study officials:
References:
citation: Moore MT, Lau MA, Haigh EAP, Willett BR, Bosma CM, Fresco DM. Association between decentering and reductions in relapse/recurrence in mindfulness-based cognitive therapy for depression in adults: A randomized controlled trial. J Consult Clin Psychol. 2022 Feb;90(2):137-147. doi: 10.1037/ccp0000718.